CAIRDAC
PrivateLast Round
Series A
Mar 31, 2022
Total Funding Raised
$18.9M
Company Overview
CAIRDAC operates in Healthcare & Life Sciences and is based in Antony. Its latest recorded funding round was a Series A round in March 2022.
CAIRDAC is a medical devices company developing ALPS (Autonomous Leadless Pacing System), a self-sustainable leadless pacemaker that harvests kinetic energy from the heart to power itself.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Health IoT, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales, Hardware + Subscription
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CAIRDAC Comparables
Compare CAIRDAC with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Abbott Laboratories | 82% | |
| Celtro GmbH | 78% | |
| Medtronic | 72% |
For institutional investors. Book with your work email.
CAIRDAC Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
CAIRDAC Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bpifrance | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 10, 2025
Grew 16% QoQ, from 31 to 36 employees.
- Jul 9, 2024
Grew 18% QoQ, from 28 to 33 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 9, 2026
Cairdac is developing ALPS(TM), a leadless pacing platform designed for dual-chamber and future conduction system pacing, and prepares the investigational device for first-in-human evaluation in France on Nov 9th '26.
- hiresSep 24, 2026
Cairdac appoints Raymond W. Cohen as chairman of its board of directors in France on Sep 24th '26.
- is_developingSep 24, 2026
Cairdac is developing ALPS on Jul 1st '26.
- hiresSep 21, 2026
Cairdac appoints Raymond W. Cohen as chairman of its board of directors on Sep 24th '26, as the pre-revenue medtech company advances its leadless, self-powered cardiac pacemaker.
For institutional investors. Book with your work email.
CAIRDAC Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about CAIRDAC's valuation, stock price, and market status.
Is CAIRDAC a public or private company?
CAIRDAC is a private company.
What is the current stock price of CAIRDAC?
CAIRDAC is a private company, so its shares have no public market price. Caplight tracks CAIRDAC's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is CAIRDAC worth (valuation)?
Valuation information for CAIRDAC is not publicly available.
Can I buy CAIRDAC stock?
CAIRDAC shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was CAIRDAC's last funding round?
CAIRDAC's most recent funding round was Series A on March 31, 2022.
Who are the main investors in CAIRDAC?
Key investors in CAIRDAC include Bpifrance.
Will CAIRDAC IPO soon?
No public IPO plans have been announced for CAIRDAC.
How can I track CAIRDAC secondary market activity?
Caplight tracks bids, offers, and trades in CAIRDAC's shares on secondary markets.